Prescient announces key hire as leading US neurosurgeon Donald M O’Rourke joins its Advisory Board
The appointment gives PTX a world-leading development team in the race to find solutions for...
The appointment gives PTX a world-leading development team in the race to find solutions for...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has appointed brain cancer specialist Professor Donald O’Rourke to...
Researchers at the University of Pennsylvania (Penn) are developing a new way for cancer-fighting CAR-T...
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke joins Small Caps...
CAR-T therapies have proven to be revolutionary treatments for cancer, but their high costs have...
Got 90 seconds? Then listen to CEO, Steven Yatomi-Clarke tell us about their company news....
Clinical-stage oncology company Prescient Therapeutics’ (ASX: PTX) strong cash position will enable it to advance its multiple...
ASX-listed oncology player Prescient Therapeutics Limited (ASX:PTX) is engaged in developing a robust drug pipeline...
Clinical-stage oncology firm Prescient Therapeutics Limited (ASX:PTX) has announced its June 2021 results, marked by...
Prescient Therapeutics (PTX) has summarised its operations and cashflow for the June quarter. The clinical-stage...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.